Christian P. Larsen
Emory University · Emory University School of Medicine: Transplantation · Emory Transplant Center, Emory University School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
9
all conditions, ClinicalTrials.gov
NIH grants tied to them
12
2 more share only the name and are not shown
Trial papers
24
PubMed author-name match
Trials
Studies that name Christian P. Larsen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06478017 · Belatacept in Heart TransplantationNational Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Heart Transplant · study chair
- Ph2NCT05518487 · COVID Protection After Transplant - Sanofi GSK (CPAT-SG) StudyNational Institute of Allergy and Infectious Diseases (NIAID) · completed · COVID-19, Kidney Transplant · study chair
- Ph2NCT05077254 · COVID Protection After Transplant-Immunosuppression ReductionNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Kidney Transplant Recipients, Liver Transplant Recipients · study chair
- Ph2NCT04903054 · Selective CD28 Blockade in Renal Transplant RecipientsNational Institute of Allergy and Infectious Diseases (NIAID) · withdrawn · Kidney Transplantation, Renal Transplant Recipients · study chair
- Ph2NCT01436305 · Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal TransplantationNational Institute of Allergy and Infectious Diseases (NIAID) · terminated · Kidney Transplantation, Renal Transplantation · principal investigator
- N/ANCT00833651 · Protective Immunity Project 02Emory University · completed · Kidney Transplant, Immunology, Immunosuppression · principal investigator
- N/ANCT00788021 · Protective Immunity Project 01Emory University · completed · Kidney Transplantation, Immunity, Immunosuppression · principal investigator
- Ph2NCT00276250 · Islet Transplantation Using AbataceptEmory University · completed · Type 1 Diabetes Mellitus
- Ph2NCT00133809 · Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free ImmunosuppressionEmory University · completed · Diabetes Mellitus, Type 1 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Selective CD28 Blockade in Renal Transplant RecipientsU01AI138909 · NIAID · EMORY UNIVERSITY · fiscal years 2018 to 2022 · $1 awarded in 2022Grant number is on one of their registry trials
- Transplant Tolerance in Non-Human PrimatesU19AI051731 · NIAID · EMORY UNIVERSITY · fiscal years 2002 to 2022 · $1,793,214 awarded in 2022Same name and institution; not confirmed by an ID
- Activation, Apathy, Anergy and Apoptosis in TransplantationR37AI040519 · NIAID · EMORY UNIVERSITY · fiscal years 2007 to 2016 · $464,653 awarded in 2016Same name and institution; not confirmed by an ID
- Preserving Renal Function & Protective Immunity Via Anti-LFA1-Based CNI AvoidanceU01AI084150 · NIAID · EMORY UNIVERSITY · fiscal years 2009 to 2011 · $2,019,903 awarded in 2011Same name and institution; not confirmed by an ID
- TRANSPLANT TOLERANCE IN NONHUMAN PRIMATESP51RR000165 · NCRR · EMORY UNIVERSITY · fiscal years 2000 to 2011 · $41,159 awarded in 2011Same name and institution; not confirmed by an ID
- INTERACTIONS OF PROTECTIVE IMMUNITY AND TRANSPLANTATION TOLERANCEP01AI044644 · NIAID · EMORY UNIVERSITY · fiscal years 1998 to 2010 · $1,101,384 awarded in 2010Same name and institution; not confirmed by an ID
- Determinants of T Cell Fate in TransplantationR01AI073707 · NIAID · EMORY UNIVERSITY · fiscal years 2008 · $387,188 awarded in 2008Same name and institution; not confirmed by an ID
- ISLET TRANSPLANTATION IN TYPE I DIABETESM01RR000039 · NCRR · EMORY UNIVERSITY · fiscal years 2004 to 2007 · $4,164 awarded in 2007Same name and institution; not confirmed by an ID
- Activation, Apathy, Anergy and ApoptosisR01AI040519 · NIAID · EMORY UNIVERSITY · fiscal years 1997 to 2006 · $333,964 awarded in 2006Same name and institution; not confirmed by an ID
- Pathogenesis/murine polyomavirus allograft nephropathyR21AI060609 · NIAID · EMORY UNIVERSITY · fiscal years 2004 to 2005 · $153,000 awarded in 2005Same name and institution; not confirmed by an ID
- MECHANISM OF COSTIMULATORY BLOCKADE RESISTANT REJECTIONU19AI044644 · NIAID · EMORY UNIVERSITY · fiscal years 1998 to 2001 · $230,705 awarded in 2001Same name and institution; not confirmed by an ID
- DENDRITIC CELL FUNCTION IN ORGAN TRANSPLANTATIONR29AI033588 · NIAID · EMORY UNIVERSITY · fiscal years 1993 to 1997 · $111,401 awarded in 1997Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Expanding HOPE Liver Transplantation: Understanding Opportunistic Infection and Cancer RiskU01AI138897 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Christine Marie Durand, DORRY L. SEGEV, AARON A TOBIAN · fiscal years 2018 to 2026Named on NCT05077254
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:34 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).Am J Transplant · 2010769 citationsRCR 21.0
- Belatacept and Long-Term Outcomes in Kidney Transplantation.N Engl J Med · 2016621 citationsRCR 23.1
- Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia.Diabetes Care · 2016512 citationsRCR 19.4
- Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.Am J Transplant · 2012250 citationsRCR 7.8
- Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.Am J Transplant · 2013150 citationsRCR 5.0
- Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).Transplantation · 2011148 citationsRCR 4.3
- Five-year safety and efficacy of belatacept in renal transplantation.J Am Soc Nephrol · 2010145 citationsRCR 3.8
- De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.Am J Transplant · 2018116 citationsRCR 4.9
- Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.Am J Transplant · 2014112 citationsRCR 3.6
- Fecal microbiota transplantation promotes reduction of antimicrobial resistance by strain replacement.Sci Transl Med · 2023102 citationsRCR 10.8